
ALPEX ACQUISITION CORP-CL A
ALPX · NASDAQ
Updated at 2026-10-15 08:21:23
- Today's High
- $9.97
- Today’s Low
- $9.97
Candlestick trends are for reference. Refer to the trading page for actual data.
Key Statistics
- Previous Open
- $9.97
- Previous Close
- $9.97
- Volume
- 100.01K
- Market Cap
- $140.17M
- P/E Ratio
- --
- EPS
- --
Previous Day Range
52-Week Range
Company Overview
- Sector
- FINANCIAL SERVICES
- Industry
- N/A
- Sub-industry
- SHELL COMPANIES
- Headquarters
- 300 DELAWARE AVE., WILMINGTON, DE, UNITED STATES, 19801
- Country
- US
- Listing Date
- 2026-06-25
- Fiscal Year End
- December
- Shares Outstanding
- 14.19M
- CIK
- 0001880995
- Website
- --
Alopexx, Inc., a clinical stage biotechnology company, focusing on developing novel immune therapeutics for the prevention, treatment, and mitigation of bacterial, fungal, and parasitic infections. The company is headquartered in Cambridge, Massachusetts.
Financial Metrics
Revenue
2022-06-30
$0
2022-03-31
$0
2021-12-31
--
Operating Expenses
2022-06-30
$524.56K
2022-03-31
$491.32K
2021-12-31
--
Net Income
2022-06-30
-$539.76K
2022-03-31
-$500.22K
2021-12-31
--
Net Profit Margin
2022-06-30
--
2022-03-31
--
2021-12-31
--
Earnings Per Share
2022-06-30
--
2022-03-31
--
2021-12-31
--
Earnings Before Interest, Taxes, Depreciation, and Amortization
2022-06-30
-$524.56K
2022-03-31
-$491.32K
2021-12-31
--
Effective Tax Rate
2022-06-30
--
2022-03-31
--
2021-12-31
--
| Item | 2022-06-30 | 2022-03-31 | 2021-12-31 |
|---|---|---|---|
| Revenue | $0 | $0 | -- |
| Operating Expenses | $524.56K | $491.32K | -- |
| Net Income | -$539.76K | -$500.22K | -- |
| Net Profit Margin | -- | -- | -- |
| Earnings Per Share | -- | -- | -- |
| Earnings Before Interest, Taxes, Depreciation, and Amortization | -$524.56K | -$491.32K | -- |
| Effective Tax Rate | -- | -- | -- |
FAQs
Risk Warning
Stock prices can be highly volatile and may rise or fall sharply in a short period. Digital asset and derivative products involve additional risks such as leverage and liquidity. Content on this page is for reference only and does not constitute investment advice. Product availability and access may vary by region and applicable regulations.